SOURCE: Frost & Sullivan

Frost & Sullivan

March 01, 2011 13:11 ET

Enhanced Product Capabilities Shore up the Preclinical Animal Imaging Systems Market, Finds Frost & Sullivan

MOUNTAIN VIEW, CA--(Marketwire - March 1, 2011) - The preclinical animal imaging systems market has weathered the consolidation in the pharmaceuticals and biotechnology industries, limited grant funding and shortage in the supply of medical isotopes by enhancing its product capabilities. In addition, the market's evolving competitive landscape and the increasing acceptance of imaging as a standard in preclinical animal research is expected to bolster it until 2016.

New analysis from Frost & Sullivan (, U.S. Preclinical Animal Imaging Systems Market, finds that the market earned revenues of $270.5 million in 2009 and estimates this to reach $676.1 million in 2016.

If you are interested in more information on this study, please send an e-mail to Britni Myers, Corporate Communications, at, with your full name, company name, title, telephone number, company e-mail address, company website, city, state and country.

Product improvements have included simplification of system operability, higher potential for clinical translation, and in some cases, significantly lower purchase and ownership costs. Meanwhile, the market's landscape is shifting with existing competitors expanding into multiple market segments and vendors with game-changing product offerings entering the fray.

"One of the most influential growth factors is the introduction of innovative imaging systems that decrease the costs and complexity of preclinical imaging," said Frost & Sullivan research analyst Roberto G. Aranibar. "Such imaging systems are broadening the range of potential end-users in the market."

These considerable product advancements notwithstanding, the systems' high purchase costs deter end users. Besides, there are also the costs associated with owning and operating traditional, advanced imaging equipment such as preclinical MRI systems. The auxiliary expenses of owning a preclinical imaging device include dedicating site construction, hiring a specialized technician and conducting system maintenance.

Moreover, the substantial downsizing and consolidation in the pharmaceuticals and biotechnology industries over the last couple of years have compelled potential industry customers to tighten their purse strings and substantially reduce preclinical research budgets.

"Relatively low-cost, easy-to-use and easy-to-site preclinical imaging systems capable of providing adequate performance in the vast majority of new and existing preclinical imaging applications are becoming more widely available," said Aranibar. "However, further market penetration may not be easily achievable until the pharmaceuticals and biotechnology industries stabilize and are able to budget the capital necessary to acquire one or more preclinical imaging systems."

Market participants have to provide quantitative proof of the cost, time and credibility benefits of imaging in research for drug and medical technology development. Equally important are their abilities to cater to the varying price needs and application pursuits of customers in both the industry and non-industry customer segments of this market.

They can hope to achieve deeper market penetration by demonstrating to pharmaceutical and biotechnology companies the ways in which imaging can ultimately lower their costs and improve success rates.

To make the most of market opportunities, vendors should make available as many different imaging modalities, as at many different price tiers as possible. This variety in product offerings and price points will help them reach out to the broadest range of customers.

U.S. Preclinical Animal Imaging Systems Market is part of the Medical Imaging Growth Partnership Services program, which also includes research in the following markets: U.S. Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) Scanners Markets; U.S. Digital and Computed Radiography (DR/CR) Markets; Teleradiology - A Study of Customer Perceptions and Trends in the U.S. Hospital Market and Western and Eastern European Markets for CT. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages 50 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 40 offices on six continents. To join our Growth Partnership, please visit

U.S. Preclinical Animal Imaging Systems Market

Contact Information